CN115243686A - 丁基苯酞及其衍生物的用途 - Google Patents

丁基苯酞及其衍生物的用途 Download PDF

Info

Publication number
CN115243686A
CN115243686A CN202180016443.8A CN202180016443A CN115243686A CN 115243686 A CN115243686 A CN 115243686A CN 202180016443 A CN202180016443 A CN 202180016443A CN 115243686 A CN115243686 A CN 115243686A
Authority
CN
China
Prior art keywords
butylphthalide
ring
administration
nbp
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180016443.8A
Other languages
English (en)
Other versions
CN115243686B (zh
Inventor
刘喜宝
李艳玲
刘洁茹
阿普菲尔斯图亚特
马玉秀
吴晓娟
王玉青
杨汉煜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHIJIAZHUAN PHARMA GROUP NBP PHARMACEUTICAL Co Ltd
Original Assignee
SHIJIAZHUAN PHARMA GROUP NBP PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHIJIAZHUAN PHARMA GROUP NBP PHARMACEUTICAL Co Ltd filed Critical SHIJIAZHUAN PHARMA GROUP NBP PHARMACEUTICAL Co Ltd
Priority to CN202410325099.6A priority Critical patent/CN118217279A/zh
Publication of CN115243686A publication Critical patent/CN115243686A/zh
Application granted granted Critical
Publication of CN115243686B publication Critical patent/CN115243686B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

本申请提供一种丁基苯酞或其光学异构体、前药、氘代物、代谢物、开环产物或开环产物的盐在制备预防、缓解或治疗周围神经病变，尤其是化疗诱发的周围神经病变的药物中的应用，以及丁基苯酞及其衍生物预防或治疗周围神经病变，尤其是化疗诱发的周围神经病变的方法。体内外研究表明，本发明所述药物能在不影响化疗药物的抑瘤功效和药代动力学特性的情况下，有效预防、缓解或治疗化疗药物引起的周围神经病变。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180016443.8A 2020-03-20 2021-03-19 丁基苯酞及其衍生物的用途 Active CN115243686B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410325099.6A CN118217279A (zh) 2020-03-20 2021-03-19 丁基苯酞及其衍生物的用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2020102025884 2020-03-20
CN202010202588 2020-03-20
CN2020107907782 2020-08-07
CN202010790778 2020-08-07
CN202011233563 2020-11-06
CN2020112335637 2020-11-06
PCT/CN2021/081817 WO2021185356A1 (zh) 2020-03-20 2021-03-19 丁基苯酞及其衍生物的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410325099.6A Division CN118217279A (zh) 2020-03-20 2021-03-19 丁基苯酞及其衍生物的用途

Publications (2)

Publication Number Publication Date
CN115243686A true CN115243686A (zh) 2022-10-25
CN115243686B CN115243686B (zh) 2024-04-09

Family

ID=77770508

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410325099.6A Pending CN118217279A (zh) 2020-03-20 2021-03-19 丁基苯酞及其衍生物的用途
CN202180016443.8A Active CN115243686B (zh) 2020-03-20 2021-03-19 丁基苯酞及其衍生物的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410325099.6A Pending CN118217279A (zh) 2020-03-20 2021-03-19 丁基苯酞及其衍生物的用途

Country Status (8)

Country Link
US (1) US20230144023A1 (zh)
EP (1) EP4122462A4 (zh)
JP (1) JP7518183B2 (zh)
KR (1) KR20220156597A (zh)
CN (2) CN118217279A (zh)
AU (1) AU2021239224B2 (zh)
CA (1) CA3175949A1 (zh)
WO (1) WO2021185356A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397272A (zh) * 2010-09-17 2012-04-04 牛锋 丁基苯酞及其衍生物在制备预防和治疗als的药物中的应用
CN102813929A (zh) * 2011-06-09 2012-12-12 沈阳药科大学 低浓度peg脂质衍生物及其应用
CN110799547A (zh) * 2017-07-05 2020-02-14 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
US20200390755A1 (en) * 2018-08-01 2020-12-17 Shaanxi Micot Technology Co., Ltd. Compound for treating nervous system diseases and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243541C (zh) 2002-05-09 2006-03-01 中国医学科学院药物研究所 2－(α－羟基戊基)苯甲酸盐及其制法和用途
CN100422133C (zh) 2003-09-01 2008-10-01 北京天衡药物研究院 2-（α-羟基戊基）苯甲酸盐及其制法和用途
CN100435792C (zh) 2004-04-23 2008-11-26 石药集团中奇制药技术（石家庄）有限公司 丁基苯酞类同系物在制备治疗抗血小板聚集和抗血栓药物中的应用
CN100554259C (zh) 2007-04-12 2009-10-28 郑州大学 2-苯并[c]呋喃酮化合物及其应用
CN101289438B (zh) 2007-04-16 2012-04-18 山东绿叶天然药物研究开发有限公司 3-(3'-羟基)-丁基苯酞酯及其制法和用途
CN101402565B (zh) 2008-11-14 2012-07-04 郑州大学 卤代2－（a－羟基戊基）苯甲酸盐及其制法和用途
CN103505409B (zh) * 2012-06-27 2017-12-26 石药集团中奇制药技术（石家庄）有限公司 一种丁苯酞注射液及其制备方法
CN104086399B (zh) 2013-07-17 2016-08-24 浙江奥翔药业股份有限公司 5-溴-2-（α-羟基戊基）苯甲酸钠盐的不同晶型及其制备方法
CN104974050A (zh) 2014-04-04 2015-10-14 上海源力生物技术有限公司 水溶性丁苯酞前药胆碱盐、其制备方法及其在医药上的应用
CN106214674B (zh) 2016-07-11 2018-10-26 华北制药集团新药研究开发有限责任公司 7-羟基-丁苯酞的医药用途
CN106432161A (zh) * 2016-07-19 2017-02-22 四川大学 一类3‑烃基‑5,6‑二氧取代苯酞化合物及其制备方法和用途
CN108084233B (zh) 2017-12-21 2020-05-08 江南大学 一种糖基修饰的丁苯酞开环衍生物的制备方法及医药用途
CN108715579B (zh) 2018-05-17 2020-03-24 四川大学 一种2-（α羟基戊基）苯甲酸的有机胺酯衍生物药物
WO2019242765A1 (zh) 2018-06-22 2019-12-26 成都海创药业有限公司 氘代丁基苯酞类化合物及其用途
CN109503548B (zh) 2018-12-26 2020-08-04 江南大学 一种丁苯酞衍生物及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397272A (zh) * 2010-09-17 2012-04-04 牛锋 丁基苯酞及其衍生物在制备预防和治疗als的药物中的应用
CN102813929A (zh) * 2011-06-09 2012-12-12 沈阳药科大学 低浓度peg脂质衍生物及其应用
CN110799547A (zh) * 2017-07-05 2020-02-14 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
US20200390755A1 (en) * 2018-08-01 2020-12-17 Shaanxi Micot Technology Co., Ltd. Compound for treating nervous system diseases and use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
SEAAB SAHIB，等: "Potentiation of spinal cord conduction and neuroprotection following nanodelivery of DL-3-n-butylphthalide in titanium implanted nanomaterial in a focal spinal cord injury induced functional outcome, blood-spinal cord barrier breakdown and edema formation", INT REV NEUROBIOL ., vol. 146, 8 July 2019 (2019-07-08), pages 153 - 188 *
兰培丽;朱俊超;孟凌新;: "牛痘疫苗接种家兔炎症皮肤提取物联合神经阻滞治疗肿瘤相关性周围神经病的疗效", 中国疼痛医学杂志, no. 10, pages 608 *
姚庆阳;李艺;唐亚梅;郑东;: "鼻咽癌放射治疗后交感神经损伤的临床表现与治疗", 实用医学杂志, no. 02, pages 44 - 46 *
张红丽;刘珊;阴均涛;闫欣;王亚飞;刘亚玲;: "丁苯酞对不同性别hSOD1~(G93A)转基因小鼠行为学的影响", 中国新药与临床杂志, no. 11, pages 56 - 59 *
王朝山;张雪辉;叶宇航;: "丁苯酞联合糖皮质激素常规治疗放射性脑病患者的价值研究", 临床医药文献电子杂志, no. 65, pages 2 - 3 *
王满良;: "丁苯酞软胶囊治疗糖尿病周围神经病变30例临床观察", 河北中医, no. 08, pages 1209 *
赵玉武;陈静炯;蒋青青;薛波;余爱勇;: "丁基苯酞治疗糖尿病性周围神经病的疗效观察", 中国神经免疫学和神经病学杂志, no. 05, pages 66 - 68 *
邓琳娜;: "新辅助化疗联合同步放化疗治疗中晚期鼻咽癌临床观察", 当代医学, no. 10, pages 1 - 2 *

Also Published As

Publication number Publication date
AU2021239224B2 (en) 2024-06-13
CA3175949A1 (en) 2021-09-23
US20230144023A1 (en) 2023-05-11
CN115243686B (zh) 2024-04-09
JP7518183B2 (ja) 2024-07-17
AU2021239224A1 (en) 2022-11-17
EP4122462A4 (en) 2024-03-20
KR20220156597A (ko) 2022-11-25
CN118217279A (zh) 2024-06-21
EP4122462A1 (en) 2023-01-25
JP2023522831A (ja) 2023-06-01
WO2021185356A1 (zh) 2021-09-23

Similar Documents

Publication Publication Date Title
TWI674898B (zh) Mcl-1抑制劑及紫杉烷化合物之組合，及其用途及醫藥組合物
CN109464460A (zh) 一种提高抗肿瘤药物敏感性的药物组合物及其在制备抗肿瘤药物中的应用
CN115006414A (zh) 人参皂苷Rg3的新用途
CN105764570B (zh) 用于克服化学治疗抗性的雷公藤内酯甲
CN112089710B (zh) 4-羟基异亮氨酸在制备抗肿瘤药物中的应用
US6548531B2 (en) Method for cancer therapy
CN115243686A (zh) 丁基苯酞及其衍生物的用途
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
RU2763544C2 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
EP4216980B1 (en) C-phycocyanin for use in the treatment and/or prevention of peripheral neuropathy
EP4275749A2 (en) Treating neuropathic pain associated with chemotherapy-induced peripheral neuropathy
JP5620391B2 (ja) リポ酸及びヒドロキシクエン酸を有効成分として含む薬学的組み合わせ
RU2812533C1 (ru) Применение бутилфталида и его производного
RU2346692C2 (ru) Применение 9-оксоакридин-10-уксусной кислоты, ее солей и сложных эфиров в комбинированной терапии рака яичников, способ лечения и наборы
TW201316990A (zh) 藥劑併用之癌治療方法
CN110742882B (zh) 刺芒柄花素在制备预防和治疗周围神经病变药物中的应用
WO2019002542A1 (en) COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
CN110693903B (zh) 一种治疗急性单核细胞白血病的药物及三氧化二砷和双氢青蒿素的应用
WO2024146555A1 (zh) 一种甲氨基秋水仙碱及盐的应用
CN114053415B (zh) Tsl-1502复方药物组合
US20240033238A1 (en) Combination of compounds for use in therapy
CN111728960B (zh) 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用
WO2022167999A1 (en) Combination therapy for cancer treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081984

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant